Updated:
Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) advances XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens.
Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) advances XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. It is initially advancing cell-based therapeutics that target the B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. The company partners with biotechnology and pharmaceutical companies to apply its PolyXen drug delivery platform, which has demonstrated an ability to improve half-life and other pharmacological properties of biologic drugs. Xenetic holds an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects royalty payments under the agreement.
General information
Firm type
Asset Manager
Frequently asked questions
Who runs investment decisions at Xenetic Biosciences?
The firm is led by CEO James Parslow, who has held the role since 2016. Board of directors provides oversight, with key decisions made by executive management. As a public company, major transactions require shareholder approval where mandated by law.
How does Xenetic Biosciences source proprietary deal flow?
Xenetic has historically licensed its glycan engineering technology from academic and commercial partners, including a key license from a Russian research institution. The firm's pipeline is built through internal R&D and opportunistic licensing of early-stage assets.
What investment stages does Xenetic typically target?
As a developer of therapeutics, Xenetic focuses on preclinical and early clinical-stage assets. It does not make external portfolio investments and has no disclosed mandate for growth equity or venture capital.
What is Xenetic's known posture on co-investments alongside external GPs?
Xenetic does not engage in co-investment transactions. Its business model is entirely focused on internal drug development, not capital management for third parties.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: